Developer docs
API playgroundTry for free, no card

Search company profiles

BioAnalysis

Full company profile

uuid0007hca

Namestring
BioAnalysis
Legal namestring
BioAnalysis LLC
Company typeenum
Private
Founded yearint
2017
Descriptiontext

BioAnalysis LLC is a Philadelphia-based, privately held non-clinical contract research organization founded in 2017, employing 11-50 staff and operating under the leadership of Founder and President Lake Paul and Director of Quality Dorie Morgan. The firm provides experimentation and problem-solving analytical services for scientific experiments, with a specialization in Analytical Ultracentrifugation (AUC) for biopharmaceutical and gene therapy developers. Its commercial focus is narrow and vertical: it targets companies that require GMP-grade analytical characterization and quality control for gene therapies and biotherapeutics.

The company's core offering is BASIS 2.0, a next-generation, GMP-compliant software platform launched in March 2026 and designed to deliver higher throughput, one-click workflows, and full compliance with FDA 21 CFR Part 11 for electronic records and electronic signatures in GMP environments. BASIS 2.0 integrates with SEDFIT, the globally recognized AUC analysis engine, and is engineered to remove the Computer Software Validation burden from clients by providing a pre-validated analytical toolchain. The platform is positioned as the firm's primary technical differentiator and anchors its analytical services delivery model.

BioAnalysis monetizes BASIS 2.0 exclusively through its own analytical services division rather than as a standalone software license, bundling software, instrumentation, and regulatory-compliant execution into a professional services engagement sold via enterprise field sales to biopharmaceutical and gene therapy clients. Pricing is not publicly disclosed, and the company has no recorded funding rounds, named enterprise customers, or disclosed revenue. Distribution is direct and global in scope but executed through the firm's own service delivery rather than third-party channels, with marketing primarily driven through industry press releases.

Short descriptiontext

BioAnalysis LLC is a Philadelphia-based non-clinical CRO offering Analytical Ultracentrifugation services bundled with its proprietary GMP-compliant BASIS 2.0 software, serving biopharmaceutical and gene therapy companies requiring FDA 21 CFR Part 11 compliant analytical characterization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
analytical ultracentrifugation, GMP-compliant software, biopharmaceutical analytical services, gene therapy characterization, FDA 21 CFR Part 11
Industry2 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Analytical Software & Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Analytical Services (Software-Enabled)
TypeProfessional Services
Description

BASIS 2.0 is available exclusively through BioAnalysis's analytical services, suggesting the company generates revenue by providing analytical testing services that leverage their proprietary GMP-compliant software. This bundled model eliminates the need for clients to perform their own Computer Software Validation.

einpresswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1BASIS 2.0
Description

Next-generation GMP-compliant software platform for Analytical Ultracentrifugation (AUC) designed for gene therapy and biotherapeutics development, offering higher throughput, one-click workflows, and full regulatory compliance with FDA 21 CFR Part 11 requirements.

einpresswire.com
Core offering1 text field

BioAnalysis provides analytical ultracentrifugation (AUC) services for gene therapy and biotherapeutics developers, delivered through its proprietary GMP-compliant software platform BASIS 2.0. The platform enables higher-throughput analytical cycles with one-click workflows and full FDA 21 CFR Part 11 compliance, eliminating the need for clients to perform their own Computer Software Validation. BASIS 2.0 is available exclusively through BioAnalysis's in-house analytical services division.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Eliminates client-side Computer Software Validation burden
Product overview1 text field

BioAnalysis provides analytical services centered around its BASIS 2.0 software platform for Analytical Ultracentrifugation (AUC). BASIS 2.0 is a GMP-compliant solution designed for gene therapy and biotherapeutics development, offering higher throughput and one-click workflows with full regulatory compliance.

Product and service1 record
1BASIS 2.0
CategoryBiopharmaceutical Analytical Software
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1SEDFIT
Strategic tierCoreTypeTechnology or Integration
Description

BASIS 2.0 integrates with SEDFIT, the globally recognized AUC analysis engine. This integration provides access to established analytical algorithms and methodologies for analytical ultracentrifugation analysis, ensuring compatibility with industry-standard analysis approaches.

einpresswire.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Fortrea (formerly Labcorp Drug Development) is a major CRO with bioanalytical and biologics characterization capabilities supporting gene therapy sponsors. It is comparable to BioAnalysis because both deliver regulated analytical testing services to biopharma clients, though Fortrea operates across the full clinical and non-clinical spectrum.

TypeBroad incumbent
Description

Malvern Panalytical (part of Spectris) supplies analytical instruments and software for particle characterization, including technologies used alongside AUC for biologics. It is comparable to BioAnalysis because both target biologics QC workflows with software-led analytical solutions.

TypeBroad incumbent
Description

Intertek provides GMP analytical testing and biologics characterization services for the pharmaceutical industry. It is comparable to BioAnalysis because both offer analytical services supporting biopharma QC and release testing, though Intertek serves a broader testing portfolio beyond AUC.

TypeBroad incumbent
Description

Eurofins BioPharma Product Testing provides GMP-compliant analytical and bioanalytical services for biologics, including gene therapies. It is comparable to BioAnalysis because both offer outsourced characterization and QC testing for biopharmaceutical manufacturers, with Eurofins operating globally and at much larger scale.

TypeEmerging player
Description

Sartorius offers analytical and purification technologies for biopharmaceutical development, including services and consumables for gene therapy analytics. It is comparable to BioAnalysis because both serve the biologics and gene therapy QC market with enabling analytical solutions.

6Cergentis
TypeEmerging player
Description

Cergentis provides specialized gene therapy analytics and characterization services, including targeted integration site analysis for cell and gene therapies. It is comparable to BioAnalysis because both are niche analytics providers serving the gene therapy/biologics market with specialized assays.

TypeBroad incumbent
Description

Thermo Fisher (via PPD) offers bioanalytical and biologics characterization services for pharmaceutical and gene therapy sponsors. It is comparable to BioAnalysis because both deliver regulated analytical services to biopharma, though Thermo Fisher operates at massive global scale.

8Wyatt Technology
TypeBroad incumbent
Description

Wyatt Technology is a leading manufacturer of light scattering and AUC instruments and also offers related analytical services for biopharma. It is comparable to BioAnalysis because both serve the biologics characterization and AUC-adjacent QC market, though Wyatt is instrument-centric while BioAnalysis focuses on software-enabled services.

TypeBroad incumbent
Description

Beckman Coulter (part of Danaher) manufactures the Optima AUC instruments that are industry standard and supports biopharma characterization workflows. It is comparable to BioAnalysis because its instruments underpin the same AUC workflows BioAnalysis services, making it a potential OEM partner or competitor in software.

TypeBroad incumbent
Description

Charles River is a large non-clinical CRO offering bioanalytical, biologics characterization, and cell/gene therapy services. It is comparable to BioAnalysis because both serve biopharma clients needing GMP-compliant analytical testing for novel biologics, though Charles River operates at vastly greater scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioAnalysis

Biopharmaceutical Analytical Software & Servicesbioanalysisllc.com

BioAnalysis LLC is a Philadelphia-based non-clinical CRO offering Analytical Ultracentrifugation services bundled with its proprietary GMP-compliant BASIS 2.0 software, serving biopharmaceutical and gene therapy companies requiring FDA 21 CFR Part 11 compliant analytical characterization.

What BioAnalysis does

BioAnalysis LLC is a Philadelphia-based, privately held non-clinical contract research organization founded in 2017, employing 11-50 staff and operating under the leadership of Founder and President Lake Paul and Director of Quality Dorie Morgan. The firm provides experimentation and problem-solving analytical services for scientific experiments, with a specialization in Analytical Ultracentrifugation (AUC) for biopharmaceutical and gene therapy developers. Its commercial focus is narrow and vertical: it targets companies that require GMP-grade analytical characterization and quality control for gene therapies and biotherapeutics.

The company's core offering is BASIS 2.0, a next-generation, GMP-compliant software platform launched in March 2026 and designed to deliver higher throughput, one-click workflows, and full compliance with FDA 21 CFR Part 11 for electronic records and electronic signatures in GMP environments. BASIS 2.0 integrates with SEDFIT, the globally recognized AUC analysis engine, and is engineered to remove the Computer Software Validation burden from clients by providing a pre-validated analytical toolchain. The platform is positioned as the firm's primary technical differentiator and anchors its analytical services delivery model.

BioAnalysis monetizes BASIS 2.0 exclusively through its own analytical services division rather than as a standalone software license, bundling software, instrumentation, and regulatory-compliant execution into a professional services engagement sold via enterprise field sales to biopharmaceutical and gene therapy clients. Pricing is not publicly disclosed, and the company has no recorded funding rounds, named enterprise customers, or disclosed revenue. Distribution is direct and global in scope but executed through the firm's own service delivery rather than third-party channels, with marketing primarily driven through industry press releases.

BioAnalysis firmographics

Firmographics
Name
BioAnalysis
Legal name
BioAnalysis LLC
Website
https://bioanalysisllc.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
BioAnalysis LLC is a Philadelphia-based non-clinical CRO offering Analytical Ultracentrifugation services bundled with its proprietary GMP-compliant BASIS 2.0 software, serving biopharmaceutical and gene therapy companies requiring FDA 21 CFR Part 11 compliant analytical characterization.
Ownership category
akta.pro rank

BioAnalysis industry classification

Industry
Product category
Biopharmaceutical Analytical Software & Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Analytical ultracentrifugation
  • GMP-compliant software
  • Biopharmaceutical analytical services
  • Gene therapy characterization
  • FDA 21 CFR Part 11

Where BioAnalysis is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

BioAnalysis business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Analytical Services (Software-Enabled): BASIS 2.0 is available exclusively through BioAnalysis's analytical services, suggesting the company generates revenue by providing analytical testing services that leverage their proprietary GMP-compliant software. This bundled model eliminates the need for clients to perform their own Computer Software Validation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

BioAnalysis product offering

Product offering

Core offering

BioAnalysis provides analytical ultracentrifugation (AUC) services for gene therapy and biotherapeutics developers, delivered through its proprietary GMP-compliant software platform BASIS 2.0. The platform enables higher-throughput analytical cycles with one-click workflows and full FDA 21 CFR Part 11 compliance, eliminating the need for clients to perform their own Computer Software Validation. BASIS 2.0 is available exclusively through BioAnalysis's in-house analytical services division.

Product overview

BioAnalysis provides analytical services centered around its BASIS 2.0 software platform for Analytical Ultracentrifugation (AUC). BASIS 2.0 is a GMP-compliant solution designed for gene therapy and biotherapeutics development, offering higher throughput and one-click workflows with full regulatory compliance.

Differentiator

Problem solved

Functional benefit

Brands

  • BASIS 2.0: Next-generation GMP-compliant software platform for Analytical Ultracentrifugation (AUC) designed for gene therapy and biotherapeutics development, offering higher throughput, one-click workflows, and full regulatory compliance with FDA 21 CFR Part 11 requirements.

Products and services

  • BASIS 2.0

Quantifiable outcome

  • Eliminates client-side Computer Software Validation burden

Companies that use BioAnalysis

Customer profile

Segments1 record

Ideal customer profiles1 record

BioAnalysis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

BioAnalysis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SEDFITcoreTechnology or IntegrationBASIS 2.0 integrates with SEDFIT, the globally recognized AUC analysis engine. This integration provides access to established analytical algorithms and methodologies for analytical ultracentrifugation analysis, ensuring compatibility with industry-standard analysis approaches.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

BioAnalysis competitors and assessment

Company assessment

Broad incumbents

  • Labcorp Drug Development (Fortrea): Fortrea (formerly Labcorp Drug Development) is a major CRO with bioanalytical and biologics characterization capabilities supporting gene therapy sponsors. It is comparable to BioAnalysis because both deliver regulated analytical testing services to biopharma clients, though Fortrea operates across the full clinical and non-clinical spectrum.
  • Malvern Panalytical: Malvern Panalytical (part of Spectris) supplies analytical instruments and software for particle characterization, including technologies used alongside AUC for biologics. It is comparable to BioAnalysis because both target biologics QC workflows with software-led analytical solutions.
  • Intertek Pharmaceutical Services: Intertek provides GMP analytical testing and biologics characterization services for the pharmaceutical industry. It is comparable to BioAnalysis because both offer analytical services supporting biopharma QC and release testing, though Intertek serves a broader testing portfolio beyond AUC.
  • Eurofins Scientific: Eurofins BioPharma Product Testing provides GMP-compliant analytical and bioanalytical services for biologics, including gene therapies. It is comparable to BioAnalysis because both offer outsourced characterization and QC testing for biopharmaceutical manufacturers, with Eurofins operating globally and at much larger scale.
  • PPD / Thermo Fisher Scientific (PPD): Thermo Fisher (via PPD) offers bioanalytical and biologics characterization services for pharmaceutical and gene therapy sponsors. It is comparable to BioAnalysis because both deliver regulated analytical services to biopharma, though Thermo Fisher operates at massive global scale.
  • Wyatt Technology: Wyatt Technology is a leading manufacturer of light scattering and AUC instruments and also offers related analytical services for biopharma. It is comparable to BioAnalysis because both serve the biologics characterization and AUC-adjacent QC market, though Wyatt is instrument-centric while BioAnalysis focuses on software-enabled services.
  • Beckman Coulter Life Sciences: Beckman Coulter (part of Danaher) manufactures the Optima AUC instruments that are industry standard and supports biopharma characterization workflows. It is comparable to BioAnalysis because its instruments underpin the same AUC workflows BioAnalysis services, making it a potential OEM partner or competitor in software.
  • Charles River Laboratories: Charles River is a large non-clinical CRO offering bioanalytical, biologics characterization, and cell/gene therapy services. It is comparable to BioAnalysis because both serve biopharma clients needing GMP-compliant analytical testing for novel biologics, though Charles River operates at vastly greater scale.

Emerging players

  • Sartorius BIA Separations: Sartorius offers analytical and purification technologies for biopharmaceutical development, including services and consumables for gene therapy analytics. It is comparable to BioAnalysis because both serve the biologics and gene therapy QC market with enabling analytical solutions.
  • Cergentis: Cergentis provides specialized gene therapy analytics and characterization services, including targeted integration site analysis for cell and gene therapies. It is comparable to BioAnalysis because both are niche analytics providers serving the gene therapy/biologics market with specialized assays.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

BioAnalysis social profiles

Digital presence

BioAnalysis compliance and trust

Trust signal

Compliance1 record

BioAnalysis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioAnalysis leadership team

Management profile

Number of profiles

Profiles2 records

BioAnalysis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioAnalysis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAnalysis

What does BioAnalysis do?

BioAnalysis provides analytical ultracentrifugation (AUC) services for gene therapy and biotherapeutics developers, delivered through its proprietary GMP-compliant software platform BASIS 2.0. The platform enables higher-throughput analytical cycles with one-click workflows and full FDA 21 CFR Part 11 compliance, eliminating the need for clients to perform their own Computer Software Validation. BASIS 2.0 is available exclusively through BioAnalysis's in-house analytical services division.

Is BioAnalysis a public or private company?

BioAnalysis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioAnalysis founded?

BioAnalysis was founded in 2017. It employs 11 to 50 people.

Where is BioAnalysis based?

BioAnalysis is headquartered in Philadelphia, United States, in the North America region.

How does BioAnalysis make money?

One revenue line is on record: analytical Services (Software-Enabled).

Who are BioAnalysis's main competitors?

Broad incumbents on record are Labcorp Drug Development (Fortrea), Malvern Panalytical, Intertek Pharmaceutical Services, Eurofins Scientific, PPD / Thermo Fisher Scientific (PPD), Wyatt Technology, Beckman Coulter Life Sciences and Charles River Laboratories. Emerging players are Sartorius BIA Separations and Cergentis.

Does BioAnalysis have an API?

No public API is recorded for BioAnalysis.

What industry is BioAnalysis in?

BioAnalysis's product category is Biopharmaceutical Analytical Software & Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireBioAnalysis Named a Civic 50 Greater Philadelphia Honoree for the Second Consecutive YearBioAnalysis LLC, a Philadelphia gene therapy analytics firm, was named a 2026 Civic 50 Greater Philadelphia honoree for the second consecutive year. The recognition, awarded by the Chamber of Commerce, highlights its community impact, and the company will celebrate at an event on November 12.EIN PresswireBioAnalysis Named a Civic 50 Greater Philadelphia Honoree for the Second Consecutive YearBioAnalysis LLC was named a 2026 Civic 50 Greater Philadelphia honoree for the second consecutive year, recognizing it as one of the region's 50 most community-minded employers. The company, based in Kensington, provides analytical services for gene therapy and biotherapeutics development. The recognition will be celebrated at the Chamber's Insights for Social Impact event.Business & FinancialBioanalysis Named A Civic 50 Greater Philadelphia Honoree For The Second Consecutive YearBioAnalysis LLC, a Philadelphia gene therapy analytics firm, was named a 2026 Civic 50 Greater Philadelphia honoree for the second consecutive year. The recognition, awarded by the Chamber of Commerce, highlights its community impact, and the company will celebrate at the Chamber's Insights for Social Impact event.EIN PresswireBioAnalysis Launches BASIS 2.0, Next-Generation GMP-Compliant AUC Software for Analytical UltracentrifugationBioAnalysis LLC announced the launch of BASIS 2.0, a next-generation GMP-compliant software platform for Analytical Ultracentrifugation (AUC) designed for gene therapy and biotherapeutics development. The new version delivers higher throughput, one-click workflows, and full regulatory compliance with FDA 21 CFR Part 11 requirements, eliminating the need for clients to perform their own Computer Software Validation. BASIS 2.0 is available exclusively through BioAnalysis's analytical services and integrates with SEDFIT, the globally recognized AUC analysis engine.PR NewswireCenter for Breakthrough Medicines and BioAnalysis LLC Form Strategic Alliance to Offer Novel Analytical Testing Services for CGT ClientsThe Center for Breakthrough Medicines (CBM) announced a strategic partnership with BioAnalysis LLC (BIA) to provide CBM's cell and gene therapy clients with access to BIA's advanced analytical testing capabilities, including viral vector characterization using BIA's proprietary sedimentation velocity analytical ultracentrifugation technology. CBM, a horizontally integrated CDMO, gains expert scientific and data analysis services from BIA, a non-clinical CRO specializing in biophysics and mass spectrometry applications for gene therapy and other biologics. The companies describe the alliance as a "game-changer" in the CGT analytical testing space, combining BIA's specialized testing capabilities with CBM's comprehensive manufacturing services.